The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data. By Ludwig Burger. March 23, 2023 4:53 PM UTC Updated March 23, 2023 Item 1 of 2 A logo on the Sanofi exhibition space ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Sanofi and Regeneron will then plot a regulatory filing for bullous pemphigoid, a rare autoimmune disease characterized by fluid-filled blisters, in 2023 and follow that up with a COPD filing ...

Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration PARIS - May 25, 2020 – Sanofi today announced its intent to sell its equity investment in ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

Sanofi controls 16.7 percent of Regeneron, or 15.82 million shares, according to Reuters data. Sanofi said in an email that it has the right to raise the stake to as much as 30 percent under ...

Dupixent, which is jointly developed by Sanofi and Regeneron Pharmaceuticals, has already racked up approvals for several indications, including asthma, atopic dermatitis, and eosinophilic ...

Regeneron Pharmaceuticals and Sanofi have launched a Phase II/III clinical program in the U.S. evaluating the marketed arthritis drug Kevzara® (sarilumab) as a treatment for severe COVID-19 ...

Sanofi announces sale of 21.6 million shares held in Regeneron Gross proceeds of $11.1 billion to Sanofi to further Company’s ability to execute innovation and growth strategy PARIS – May 26 ...